Raymond James Financial
TARA icon

Raymond James Financial’s Protara Therapeutics TARA Stock Holding History

Raymond James Financial’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-271
Closed -$821 – 6585
2025
Q2 		$821 Buy
+271
New +$935 ﹤0.01% 6598

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Raymond James Financial's TARA Position: Q3 2025 in Review

Raymond James Financial sold out of Protara Therapeutics (TARA) in Q3 2025, closing a stake of 271 shares — an estimated $821 sold.

Raymond James Financial first reported a position in TARA in Q2 2025 and held it in 1 quarter. The position peaked at $821 in Q2 2025. 81 funds tracked by Wall St. Rank hold TARA as of Q3 2025.

  • Raymond James Financial reported no remaining Protara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 271 Protara Therapeutics shares in Q3 2025, an estimated $821.
  • Raymond James Financial first reported a position in Protara Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Protara Therapeutics position peaked at $821 in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.